MARKET

PRLD

PRLD

Prelude Therapeutics Inc
NASDAQ
4.740
-0.030
-0.63%
Closed 16:00 03/28 EDT
OPEN
4.800
PREV CLOSE
4.770
HIGH
4.995
LOW
4.720
VOLUME
32.07K
TURNOVER
0
52 WEEK HIGH
8.57
52 WEEK LOW
1.660
MARKET CAP
260.32M
P/E (TTM)
-2.3483
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PRLD last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at PRLD last week (0311-0315)?
Weekly Report · 03/18 09:26
Despite Recent Gains, Prelude Therapeutics Insiders Are Still Down US$19k
Insiders purchased US$117.0k worth of Prelude Therapeutics Incorporated shares over the past year. The company's share price has risen 11% in the last week. Insiders made losses of US$19k since the purchase of shares. In the last 12 months Prelude TherAPEutics insiders were buying shares, but not selling. It's a good sign to see if insiders are buying shares at higher prices. Prelude Therapedutics insiders own 5.9% of the company.
Simply Wall St · 03/14 10:03
Prelude Therapeutics Initiated at Market Outperform by JMP Securities
Dow Jones · 03/13 09:30
Prelude Therapeutics Price Target Announced at $7.00/Share by JMP Securities
Dow Jones · 03/13 09:30
JMP Securities Initiates Coverage On Prelude Therapeutics with Market Outperform Rating, Announces Price Target of $7
Benzinga · 03/13 09:20
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)
TipRanks · 03/13 04:30
Weekly Report: what happened at PRLD last week (0304-0308)?
Weekly Report · 03/11 09:26
More
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Webull offers Prelude Therapeutics Inc stock information, including NASDAQ: PRLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRLD stock methods without spending real money on the virtual paper trading platform.